<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)*
NABI
------------------------------------------
(Name of Issuer)
Common Stock, par value $ .10 per share
------------------------------------------
(Title of Class of Securities)
628716102
------------------------------------------
(CUSIP Number)
Jose M. de Lasa, 100 Abbott Park Road
Abbott Park, Illinois 60064-6049; Phone 847 937 8905
------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
June 2, 2000
------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the following
box [_].
NOTE: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies
should be sent.
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
<PAGE>
CUSIP No. 628716102
-------------------------------------------------------------------------------
1) NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Abbott Laboratories
IRS Identification No. 36-0698440
-------------------------------------------------------------------------------
2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
-------------------------------------------------------------------------------
3) SEC USE ONLY
-------------------------------------------------------------------------------
4) SOURCE OF FUNDS
Not Applicable
-------------------------------------------------------------------------------
5) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e) [ ]
-------------------------------------------------------------------------------
6) CITIZENSHIP OR PLACE OF ORGANIZATION
Illinois
-------------------------------------------------------------------------------
NUMBER OF (7) SOLE VOTING POWER
SHARES 1,630,000
BENEFICIALLY (8) SHARED VOTING POWER
OWNED BY 0
EACH (9) SOLE DISPOSITIVE POWER
REPORTING 1,630,000
PERSON WITH (10) SHARED DISPOSITIVE POWER
0
-------------------------------------------------------------------------------
11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,630,000
-------------------------------------------------------------------------------
12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES (SEE INSTRUCTIONS) [ ]
-------------------------------------------------------------------------------
13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.56% (see Item 5 below)
-------------------------------------------------------------------------------
14) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
-------------------------------------------------------------------------------
Page 2 of 4 pages
<PAGE>
The following information amends and supplements the original Schedule 13D
filed by Abbott Laboratories ("Abbott") on October 19, 1992.
ITEM 1. SECURITY AND ISSUER
This statement relates to shares of the common stock, par value $ .10
per share (the "Common Stock"), of NABI, a Delaware corporation (the
"Issuer"), whose principal executive offices are located at 5800 Park of
Commerce Boulevard N.W., Boca Raton, Florida 33487.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
(a) As of June 6, 2000, Abbott Laboratories ("Abbott") was the
beneficial owner of 1,630,000 shares of Common Stock (the "Shares"),
representing approximately 4.56% of the outstanding shares of the Common
Stock. The calculation of the foregoing percentage is based on the number of
shares of Common Stock shown as being outstanding on the Form 10-Q Quarterly
Report filed by the Issuer with the Securities and Exchange Commission for
the quarterly period ended April 1, 2000.
(b) Abbott has sole power to vote or to direct the vote and the sole
power to dispose or to direct the disposition of the Shares.
(c) In the past 60 days, Abbott has effected the following open market
sales of the Common Stock:
<TABLE>
<CAPTION>
Date Number of Shares Sold Average Price Per Share
---- --------------------- -----------------------
<S> <C> <C>
May 17, 2000 10,000 $5.6406
May 18, 2000 10,000 $5.5000
May 19, 2000 25,000 $5.1750
May 22, 2000 10,000 $5.2500
May 23, 2000 20,000 $5.4375
May 24, 2000 20,000 $5.0000
May 25, 2000 5,000 $5.3125
May 26, 2000 15,000 $5.0000
May 30, 2000 40,000 $5.0781
May 31, 2000 35,000 $5.5000
June 1, 2000 10,000 $5.8125
June 2, 2000 40,000 $5.5781
June 5, 2000 30,000 $5.3542
June 6, 2000 100,000 $5.5313
</TABLE>
Page 3 of 4 pages
<PAGE>
(e) On June 2, 2000, Abbott ceased to be the beneficial owner of more
than five percent of the Common Stock.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
Abbott Laboratories
DATED: June 12, 2000 By: /s/ Gary P. Coughlan
--------------------------------------
Gary P. Coughlan, Senior Vice President,
Finance and Chief Financial Officer
Page 4 of 4 pages
